Cognition Therapeutics: Dementia with Lewy Bodies R&D Symposium

Ms. Ricciardi has served as Cognition Therapeutics’ chief executive officer and president since March 2020 and as a member of our board of directors since March 2019. During her career, she has served as CEO of Suono Bio, SVP of global corporate & business development of Foundation Medicine, and SVP of U.S. and international business development of Express Scripts. Previously, Ms. Ricciardi was in the commercial division of Pfizer Inc., where she led the launch of three drugs before being appointed by the chairman to run global business development.

Dr. Caggiano has broad experience in the development of new medicines for neurological conditions. Prior to joining Cognition, Dr. Caggiano was chief medical officer and head of R&D for Neurotrauma Sciences, a biopharmaceutical company developing therapies to treat the effects of stroke and TBI. Earlier, during a 17-year career at Acorda Therapeutics, he oversaw preclinical and clinical development programs in neurological conditions such as multiple sclerosis, stroke and spinal cord injury.

Dr. Hamby is Cognition Therapeutics’ VP of research and leads the company’s effort to identify pharmacodynamic biomarkers for our neurodegenerative and neuro-ophthalmology programs. Prior to joining Cognition Therapeutics, Dr. Hamby was the head of neuroinflammation at the Neurodegeneration Consortium at MD Anderson and earlier was a scientist at Lundbeck, where she helped guide nomination of the lead candidates for various CNS disorders.

Dr. Galvin is a professor of neurology and the director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine (UM). In addition, he the chief of neurology cognitive sciences for Palm Beach and Broward County, Florida. He has over 25 years of experience in clinical care and research of dementia with Lewy bodies. Dr. Galvin’s research has focused on the underlying cause of disease and how to improve diagnosis, disease characterization and patient care. Dr. Galvin is a member of LBDA’s Scientific Advisory Council and Board of Directors.

Angela Taylor is the senior director of research and advocacy for the Lewy Body Dementia Association (LBDA). She plays a hands-on role in LBDA's Research Centers of Excellence program, patient engagement, and educational initiatives at LBDA. Bringing a personal connection as a former LBD caregiver, she is a regularly invited speaker at scientific conferences and outreach events. Angela is also a former member of the Advisory Council on Alzheimer's Research, Care and Services.